Enrolling for new upper tract urothelial cancer clinical trial

Emory Urology recently opened a new clinical trial for enrollment. Dr. Ken Ogan is leading a multicenter Phase 3 study focusing on assessing the safety and efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy for treating low-grade Upper Tract Urothelial Cancer (UTUC). The study includes individuals with new or recurrent low-grade, non-invasive UTUC confirmed via biopsy. Patients with multifocal, smaller tumors are eligible. Treatment involves intravenous administration of a single dose of the medication, followed by activation via laser light, utilizing the technique of Vascular-Targeted Photodynamic (VTP) therapy. Please send any referrals to “Research Urology Pool” via EPIC, or by emailing [email protected] .